BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Big FDA review coming this July. Here's what athletes and patients should know about BPC 157, TB 500, and the broader peptide conversation. Always speak with your physician before starting any new protocol. #bpc157 # Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling